---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-005157"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-04-22T23:59:59+00:00"
generated_at: "2026-05-23T09:14:26.128470+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Coherus announces CCO Paul Reider resignation effective April 30, 2025

## Summary
- Paul Reider resigned as CCO and employee effective April 30, 2025, to pursue other opportunities.
- Resignation follows completion of UDENYCA franchise divestiture; not due to any disagreement.
- Severance includes 12 months base salary and COBRA reimbursement through Dec 31, 2026.
- Vesting extended for unvested equity through Dec 31, 2026; option exercise period extended.
- Reider will advise executive leadership on a part-time basis until April 30, 2026.

## SEC filing metadata
- accession: 0001558370-25-005157
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-04-22T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025005157/0001558370-25-005157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025005157/chrs-20250416x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-005157
- JSON: https://secwatch.observer/filing/0001558370-25-005157.json
- Plain text: https://secwatch.observer/filing/0001558370-25-005157.txt

## Key facts
- Executive change
  Paul Reider resigned as Chief Commercial Officer at Coherus Oncology, Inc..
  - Action: resigned
  - Role: Chief Commercial Officer
  source text: Paul Reider notified Coherus BioSciences, Inc. (the “Company”) on April 16, 2025 of his resignation as Chief Commercial Officer and employee of the Company effective on April 30, 2025 in order to pursue other opportunities
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837025005157/0001558370-25-005157-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.